ArticleHLA2026
Full-Length Next-Generation Sequencing of 11 HLA Loci of More Than 1000 Individuals From Clinical Cohorts in East and West Africa.
Article in HLA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
16 authors.
Funding
Abstract
HLA loci have been implicated in several diseases, including HIV-1, from different world populations. It is necessary to characterise HLA allele variation at the population level prior to investigating associations linked to human diseases. In global databases, limited high-resolution HLA allele types generated by next-generation sequencing (NGS) have been described for populations from African countries. We sought to expand our NGS-based HLA genotyping database to include a total of 1023 participants from multiple clinical studies using a contiguous full-length gene sequencing approach. Collectively we describe HLA genotypes of individuals from Kenya (N = 375), Uganda (N = 338), Nigeria (N = 139), Tanzania (N = 89) and Mozambique (N = 82). Overall, we identified 362 unique HLA alleles across 11 loci with the most frequent at each locus being A*02:01:01, B*53:01:01, C*04:01:01, C*06:02:01, DPA1*01:03:01, DPB1*01:01:01, DQA1*01:02:01, DQB1*06:02:01, DRB1*15:03:01, DRB3*02:02:01, DRB4*01:03:01 and DRB5*01:01:01. A total of 24 novel alleles (HLA-A (2), B (1), C (1), DPA1 (4), DPB1 (6), DQA1 (3), DRB1 (6) and DRB3 (1)) were identified, including 3 (C*07:1218, DQA1*01:190 and DPB1*1820:01) with non-synonymous changes affecting the peptide binding groove of HLA molecules. This expansion of NGS based HLA data at the African population level will improve our understanding of human genetic variation and provide insights for disease association, vaccine development and targeted personalised therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.